Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 11:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
0.295 ^CAD	0.00%		0.00%	-68.28%

Apr. 24	Antibe Therapeutics Inc. Announces Board Resignations	CI
Apr. 19	Antibe Therapeutics Seeks Extension of Stay of Proceedings	MT

Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul

September 28, 2023 at 07:00 am EDT

Antibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.

Latest news about Antibe Therapeutics Inc.

Antibe Therapeutics Inc. Announces Board Resignations	Apr. 24	CI
Antibe Therapeutics Seeks Extension of Stay of Proceedings	Apr. 19	MT
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	Apr. 16	MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review	Apr. 16	MT
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	Apr. 09	MT
Antibe Therapeutics Inc. Announces Board Resignations	Apr. 09	CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	Apr. 01	DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	Apr. 01	DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	Apr. 01	CI
Antibe Therapeutics Inc. Announces Formation of Executive Committee	Apr. 01	CI
Antibe Therapeutics Brief: Says to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	Mar. 20	MT
Antibe Therapeutics Brief: To Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting Tomorrow	Mar. 07	MT
Antibe Therapeutics Announces Unfavorable Decision in Arbitration With Nuance Pharma	Mar. 04	MT
Antibe Reported Q3 2024 Interim Financial and Operating Results	Feb. 14	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Antibe Extending Early Warrant Exercise Incentive Program	Feb. 01	MT
Antibe Therapeutics Announced Early Warrant Exercise Incentive Program	Dec. 29	MT
Antibe Therapeutics Up 4% After Announcing Amendment To Warrant Extension, Price Changes	Dec. 12	MT
Antibe Therapeutics Reports Q3 2023 Net and Comprehensive Loss of $5 Million	Nov. 13	MT
Antibe Therapeutics Brief: For Quarter ended September 30, 2023, Net Loss and Comprehensive Loss totaled $5.0 million ($0.10 per share)	Nov. 13	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul?s New Formulation	Nov. 09	CI

Chart Antibe Therapeutics Inc.

Duration

Period

More charts

Company Profile

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Companyâs pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.295 CAD

Average target price

2 CAD

Spread / Average Target

+577.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTIBE THERAPEUTICS INC.	-68.28%	11.42M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs